1. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution
- Author
-
Llucia Alos, F A Moreno, Joseph Malvehy, G Villacampa, Marcelo Sánchez, I Valduvieco, G R Ares, E Carcelero, M M Estébanez, R Rull, R Martin-Huertas, Cristina Teixidó, A.M. Arance Fernandez, C.M. Vila, Pedro Jares, H S Oberoi, and P Dashti
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Proportional hazards model ,business.industry ,Melanoma ,Ipilimumab ,General Medicine ,medicine.disease ,Regimen ,Internal medicine ,Cutaneous melanoma ,Cohort ,medicine ,Nivolumab ,business ,medicine.drug - Abstract
We retrospectively analysed overall survival (OS) and potential predictive biomarkers of OS in patients with metastatic melanoma treated with ipilimumab plus nivolumab in a single institution. Electronic medical records of patients with advanced melanoma receiving ≥ 1 dose of a combined ipilimumab plus nivolumab regimen between March 3, 2016 and March 7, 2020 in a single institution, were reviewed. OS was analysed using the Kaplan–Meier method. Sub-group analyses were conducted to examine several endpoints according to relevant clinical, molecular and pathological variables using logistic and Cox models. Forty-four cases were reviewed, 38 (86.4%), of whom had cutaneous melanoma, 21 (47.7%) were BRAF mutant, 21 (47.7%) presented high lactate dehydrogenase (LDH) values, 23 (52.3%) had ≥ 3 disease sites, and 10 (22.7%) patients had brain metastases. The median follow-up was 37.7 months, and the median OS was 21.1 months (95% CI 8.2–NR). In the multivariate analysis, the OS was significantly longer in patients with an Eastern Cooperative Oncology Group (ECOG) score of 0, LDH ≤ upper limit of normal, absence of liver metastases and neutrophil-to-lymphocyte ratio (NLR)
- Published
- 2021
- Full Text
- View/download PDF